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Abstract
OBJECTIVES—PECAM-1 is a member of the superfamily of immunoglobulins (Ig) and is
expressed on platelets at moderate level. PECAM-1 has been reported to have contrasting effects
on platelet activation by the collagen receptor GPVI and the integrin, αIIbβ3, even though both
receptors signal through Src-kinase regulation of PLCγ2. The present study compares the role of
PECAM-1 on platelet activation by these two receptors and by the lectin receptor, CLEC-2, which
also signals via PLCγ2.
METHODS & RESULTS—Studies using PECAM-1 knockout-mice and cross-linking of
PECAM-1 using specific antibodies demonstrated a minor inhibitory role on platelet responses to
the above three receptors and also under some conditions to the G-protein agonist thrombin. The
degree of inhibition was considerably less than that produced by PGI2, which elevates cAMP.
There was no significant difference in thrombus formation on collagen in PECAM-1−/− platelets
relative to litter-matched controls.
CONCLUSIONS—The very weak inhibitory effect of PECAM-1 on platelet activation relative to
that of PGI2 indicate that the Ig-receptor is not a major regulator of platelet activation.
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INTRODUCTION
Inhibition of platelet activation is an essential component of physiological blood flow,
preventing formation of thrombus in healthy vessels and limiting thrombus growth during
haemostasis. The two major, direct inhibitors of platelet function are nitric oxide (NO) and
prostacyclin (PGI2) [1]. NO is constitutively released from endothelial cells and has a short
half-life in the vasculature of 3-5 seconds which means that the highest concentration of this
gaseous transmitter is found in the vicinity of the endothelial cell, a key site of inhibition of
platelet function. Its effects are mediated through activation of guanylyl cyclase [2]. This
leads to generation of cGMP and activation of protein kinase G (PKG) which in turn inhibits
type-III phosphodiesterase resulting in an elevation of cAMP. PGI2 is synthesized by
endothelial cells from arachidonic acid and activates the Gs-coupled seven transmembrane
IP-receptor, which regulates adenylyl cyclase resulting in cAMP formation [3]. Activation
Correspondence: Dr Tarvinder Dhanjal Centre for Cardiovascular Sciences, Institute of Biomedical Research, Division of Medical
Sciences, The Medical School, University of Birmingham, Birmingham, B15 2TT, UK. Fax Number: 01214158817 Telephone
Number: 01214158678 Email: t.s.dhanjal@bham.ac.uk.
Europe PMC Funders Group
Author Manuscript
Platelets. Author manuscript; available in PMC 2007 March 19.
Published in final edited form as:
Platelets. 2007 February ; 18(1): 56–67. doi:10.1080/09537100600881396.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
of protein kinase A (PKA) by cAMP and PKG by cGMP inhibit platelet activation through
several mechanisms including promoting calcium extrusion and inhibition of phospholipase
C (PLC) [4-6].
Recent studies have suggested that Platelet Endothelial Cell Adhesion Molecule-1
(PECAM-1 or CD31) is also an important regulator of platelet inhibition [7-10]. PECAM-1
is a 130kDa member of the immunoglobulin superfamily that is expressed on the surface of
circulating platelets at a moderate level (∼10,000 copies/cell) [11-13]. In addition,
PECAM-1 is expressed on endothelial cells, monocytes, neutrophils and in humans, naïve
subsets of T-cells and B-cells [14, 15]. PECAM-1 has 6 extracellular Ig-domains, a short
transmembrane region and a 118 amino acid cytoplasmic tail that contains 2
immunoreceptor tyrosine-based inhibition motifs (ITIMs) at positions 663 and 686 [16]. The
amino terminal Ig-domain mediates homophilic binding between PECAM-1 molecules on
adjacent cells. PECAM-1 plays a critical role in many processes within the vasculature
including transendothelial migration, apoptosis, angiogenesis, anaphylaxis and wound-
healing [14, 15, 17-23].
Many of the actions of PECAM-1 are mediated by upregulation of adhesion through β1, β2
and β3 integrins [17, 24-27]. For example, T-cells treated with bivalent PECAM-1
monoclonal antibodies (mAbs) exhibit increased adherence to plastic wells coated with
fibronectin or VCAM-1 [17]. Similarly, ligation of PECAM-1 leads to upregulation of β2
integrin function in lymphokine-activated killer cells, monocytes, neutrophils and natural
killer cells [18, 24, 25]. Indeed, in initial studies in platelets, a mAb to the 6th Ig-domain of
PECAM-1 was observed to augment platelet deposition onto extracellular matrix and to
enhance aggregation to ADP and PAF [28].
However more recent studies based on PECAM-1-deficient mice, and with other PECAM-1
antibodies and recombinant PECAM-1 encompassing the six Ig-domains, have provided
evidence that the major role of PECAM-1 in platelets is inhibitory [8, 9]. Two studies on
PECAM-1 knockout-mice have provided evidence for an inhibitory role for PECAM-1 in
aggregation to low but not high concentrations of collagen and the GPVI-specific agonist,
collagen-related peptide (CRP) [8, 9]. In addition, a further study on PECAM-1 knockout-
mice has provided evidence for a similar inhibitory role of PECAM-1 against platelet
spreading and aggregation induced by von Willebrand factor (VWF)-ristocetin, which also
signals through the FcR γ-chain [10]. Importantly, thrombus formation on collagen at high
shear (1800s−1), but not on VWF at a similar rate of shear (1500s−1), is potentiated in
PECAM-1−/− mice. Cross-linking of PECAM-1 using specific antibodies or recombinant
PECAM-1 also leads to inhibition of platelet activation by collagen [29]. Interestingly,
crosslinking studies using PECAM-1 antibodies have also revealed a weaker inhibitory
effect against platelet activation by the G protein-coupled receptor ligands, thrombin and
U46619 [29].
Despite the increasing recognition of the inhibitory role of PECAM-1 in platelets, a number
of recent observations indicate a more complex picture and have also begun to cast doubt on
the molecular basis of the inhibitory action. For example, PECAM-1 has recently been
shown to be essential for spreading and to have a major stimulatory role in regulating clot-
retraction induced by the major platelet integrin, αIIbβ3, thereby demonstrating that it also
contributes to platelet activation [30]. Furthermore, Wee and Jackson have shown that
potentiation of aggregation to CRP in PECAM-1−/− mice is not mediated by an increase in
intracellular Ca2+, thereby demonstrating its inhibitory role is not due to inhibition of ITAM
regulation of PLCγ [30].
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The role of PECAM-1 in the regulation of platelet function in vivo is also less clear in view
of a number of contrasting observations and presence of PECAM-1 on endothelial cells. An
initial, intravital-microscopy study used a helium-neon laser in the presence of intravascular
Evans blue to injure the endothelium of arterioles on the surface of the mouse brain [31].
This study led to the conclusion that exposed PECAM-1 on endothelium promotes platelet
adhesion and aggregation. A subsequent intravital study analysing photochemically-induced
thrombus in microvessels of the cremaster muscle concluded that PECAM-1 was not
critically involved in thrombus formation upon endothelial cell injury [32]. However, more
recently it has been reported that thrombi formed in PECAM-1-deficient mice are slightly
larger, form more rapidly and are more stable than those in control mice following a heat-
induced endothelial injury model which does not lead to collagen exposure [7]. Furthermore,
this study used radiation-chimeric mice to demonstrate that this effect was not due to the
presence of PECAM-1 on endothelial cells. On the other hand, in the same study, this group
demonstrated that PECAM-1 plays a negligible role in a more severe model of thrombus,
namely ferric chloride injury of the carotid arteries. Thus, these data point to a growing
recognition that the role of PECAM-1 in vivo may vary between vascular beds and with the
nature of the injury.
In view of the confusion surrounding the action of PECAM-1 on platelets, the present study
was undertaken to compare the role of PECAM-1 in platelet activation by GPVI, integrin
αIIbβ3 and the C-type lectin receptor, CLEC2, which also signals through PLCγ2 [33].
Importantly studies were performed using both PECAM-1 knockout-mice and crosslinking
of PECAM-1 using specific antibodies so as to enable a full comparison to previous studies.
The results demonstrate that PECAM-1 has a minor inhibitory effect on platelet activation
by tyrosine kinase-linked receptors, which is considerably smaller than of PGI2.
Furthermore, at a physiological rate of flow, thrombus formation on collagen is not altered
in the absence of PECAM-1, thus questioning its physiological significance.
MATERIALS AND METHODS
Materials and antibodies
The synthetic CRP peptide GCP*(GPP*)10GCP*G (where P* denotes a hydroxyproline
amino acid residue) was cross-linked through N- and C-terminal cysteine residues as
previously described [34, 35]. Fibrillar-type I Horm collagen from equine tendon was from
Nycomed (Axis-Shield, UK). Human fibrinogen, depleted of plasminogen, VWF and
fibronectin was from Enzyme Research (Swansea, UK). Rhodocytin was kindly provided by
Dr Johannes Eble (Muenster, Germany). FcγRIIA specific monoclonal antibody (IV.3) was
from Madarex Inc (Annandale, NJ) and F(ab')2 fragments were generated using immobilized
pepsin according to manufacturer's instructions. The functional integrity of IV.3 F(ab')2
fragments was confirmed by their inability to induce FcγRIIA–receptor-mediated platelet
activation after crosslinking using a secondary antibody. PECAM-1 knockout-mice were a
gift from Dr Tak Mak (Amgen Institute, Toronto, Ontario, Canada). PECAM-1−/− mice
were housed under pathogen-free conditions at the University of Birmingham Animal SPF
facility under National Health and Medical Research Council guidelines and approved
animal protocols. PECAM-1−/− mice were bred from heterozygotes on a C57Bl6
background. The phenotype of the PECAM-1−/− was confirmed by flow cytometric analysis
of leukocytes [21]. Anti-human PECAM1.3 IgG1 mAb was a gift from Prof. Peter Newman
(Blood Research Institute, Milwaukee, WI, USA). PECAM-1 mAb AB468 was from
Autogen-Bioclear (Wiltshire, UK). Sheep anti-mouse IgG F(ab')2 fragments, a mouse IgG1
isotype control and bovine plasma thrombin were purchased from Sigma (Poole, UK). mAb
AB468 and control IgG1 were dialysed prior to experimentation to remove azide.
PD0173952 was a gift from Pfizer Global Research & Development (Ann Arbor, MI, USA
and Sandwich, UK).
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Platelet aggregation studies
Blood was obtained from consenting donors who had not taken any anti-platelet medication
within the preceding 2 weeks. To prepare washed platelets, whole blood was anticoagulated
with 10% acid-citrate-dextrose (ACD; 80mM citric acid, 120mM sodium citrate, 110mM
glucose). The blood was centrifuged at 200 g for 20min and the platelet-rich-plasma (PRP)
removed. PGI2 (800nM) was added to the PRP which was then centrifuged at 1000 g for
10min to pellet the platelets. The platelet-poor-plasma was decanted and the pellet
resuspended in 10ml of the following Ca2+-free modified Tyrodes-HEPES buffer (134mM
NaCl, 2.9mM KCl, 12mM NaHCO3, 0.34mM Na2HPO4, 20mM HEPES [N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid], 5mM glucose, and 1mM MgCl2, pH 7.3)
in the presence of prostacyclin (1μM). The resuspended platelets were centrifuged at 1000
g, the supernatant discarded, and the platelets resuspended with the appropriate volume of
modified Tyrodes-HEPES buffer to 2×108 platelets/ml. Aggregation studies were performed
in siliconized glass cuvettes at 37°C with constant stirring at 1000 rpm in a Born
aggregometer. Platelet aggregation was initiated by addition of CRP, collagen, thrombin or
rhodocytin and was detected by changes in light transmission. Wild-type C57/BL6 and
PECAM-1−/− C57/BL6 litter-matched mice were halothaneasphyxiated and bled by cardiac
puncture into 0.1% ACD. Anticoagulated whole blood was then centrifuged at 200 g for
5min at room temperature and PRP isolated. Platelets were washed twice using a modified
Tyrode-HEPES buffer and resuspended at 2 × 108 /ml.
Platelet Spreading Assay
Washed murine platelets (6 × 107 /ml) were incubated on CRP- or fibrinogen-coated
coverslips at 37°C for 45min in a humid environment. Platelet spreading was imaged in real-
time using Kohler illuminated Nomarski differential interference contrast optics with a Zeiss
63X oil immersion 1.40 NA axioplan lens on a Zeiss Axiovert 100 Microscope. Time-lapse
events were captured by QICAM Mono 10-bit camera (QImaging, Burnaby, BC, Canada)
using Openlab software for Macintosh. To compute the surface area of spreading platelets,
time-lapse images were manually outlined and quantitated by determining the number of
pixels within each outline using a Java plugin for the Image-J software package. Imaging a
graticule under the same conditions allowed the conversion of pixels size to microns.
Clot Retraction Assay
Whole murine blood was anti-coagulated with sodium citrate and PRP prepared as above.
The platelet count was adjusted to 3 × 108 /ml with Tyrodes-HEPES containing CaCl2
(2mM) and fibrinogen (2mg/ml). 400μl of the adjusted PRP/Tyrodes-HEPES/Fib/CaCl2 mix
was placed in an aggregometer tube and incubated at 37°C for 5min. 2μl of mouse
erythrocytes were added for colour contrast. Thrombin (10U/ml) was added and mixed with
a paper-clip and clot retraction was allowed to proceed at 37°C for 2 hours with the paper-
clip present. At appropriate time points photographic images of retracting clots were
recorded. The clot was pulled out with the paper-clip and the remaining serum volume
measured. These experiments were performed blind.
Flow adhesion assay
Mouse blood was taken into 40μM P-PACK with sodium heparin (5U/mL) by cardiac
puncture. The blood was perfused through a glass microslide, 1 × 0.1mm inner diameter
(Camlab, Cambridge, UK), the luminal surface of which had been coated with 100μg/ml
type-I collagen from equine tendon (Horm; Nycomed, Munich, Germany) before blocking
with 2% BSA in phosphate-buffered saline. Shear rate of 1800s−1 with perfusion for 3min
was generated by a syringe pump (Harvard Apparatus, Southnatick, MA). After perfusion
with whole blood, modified Tyrode-HEPES buffer was perfused for 8min at the same shear
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rate as the blood. Platelet thrombi that had formed on the surface of the collagen were
visualized with an inverted stage videomicroscope system (DM IRB; Leica, Milton Keynes,
UK) and surface coverage was analyzed using Image-Pro Plus software (Media Cybernetics,
Silver Spring, MD). Subsequently adherent platelets were lysed in ice-cold nonidet P-40
(NP-40) lysis buffer (20 mM Tris [tris(hydroxymethyl)aminomethane], 300mM NaCl, 2mM
EGTA, 2mM EDTA, 2% [vol/vol] NP-40, 1mM phenylmethylsulphonyl fluoride, 2mM
Na3VO4, 10μg/ml leupeptin, 10μg/ml aprotinin, 1μg/ml pepstatin A, pH 7.3) for protein
estimation using RC-DC protein assay (Bio-Rad, Hemel Hempsted, UK). These experiments
were performed blind.
Cross-Linking Experiments
Washed human platelets (400μl at 2×108 /ml) were stimulation with CRP, collagen and
thrombin and platelet aggregation was measured with a Born optical platelet aggregometer
with continuous stirring (1000 rpm). PECAM-1 was stimulated by incubation with anti–
PECAM-1 antibodies, PECAM1.3 or AB468 (1-5μg/ml) for 2min, followed by incubation
for 2min with F(ab')2 fragments of sheep anti-mouse anti-IgG secondary antibodies (30μg/
ml) to cross-link. The binding epitope of PECAM1.3 has been mapped to immunoglobulin
domain 1 [36]. Control experiments were performed using an equal concentration of mouse
IgG1 isotype-matched control antibody in place of PECAM1.3 or AB468. In all
experiments, the low-affinity FcγRIIA receptor for IgG was blocked by incubation with a
saturating concentration (1μg/ml) of F(ab')2 fragments of mAb IV.3 for 2min. Saturating
concentrations of mAb IV.3 antibody were established by determining the concentration of
F(ab')2 fragment that completely inhibited subsequent IgG–mediated FcγRIIA crosslinking
and platelet activation. Platelet aggregation was determined by optical aggregometry.
Immunoprecipitations and immunoblotting
Platelet stimulation was terminated by the addition of an equal volume of ice-cold lysis
buffer. Cell lysates were precleared with protein-A sepharose overnight at 4°C prior to
immunoprecipitations. Cell debris was removed by centrifugation for 5min at 13000 g at
4°C. Supernatants were collected and PECAM-1 was immunoprecipitated with PECAM1.3
antibody. Control samples were immunoprecipitated with an anti-IgG isotype antibody.
Soluble cell lysates and immunoprecipitates were resolved on 10% sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels, transferred to polyvinylidene
diflouride (PVDF) membranes using a semi-dry transfer system (Trans-blot SD. BioRad
Laboratories, Hertfordshire, UK) and immunoblotted. Proteins were detected by incubating
membranes with enhanced chemiluminescence reagents (Amersham Biosciences, Bucks,
UK) followed by exposure to hyperfilm MP (Amersham Biosciences, Bucks, UK).
Analysis of Data
All experiments were performed a minimum of 3 times and images shown are representative
data from one experiment with data shown as means±SEM. Statistical analysis was
conducted using 2-tailed Student unpaired t test and statistical significance of differences
between means was determined by one-way ANOVA. If means were shown to be
significantly different, multiple comparisons by pairs were performed by the Tukey test. A
chi-squared test was used to determine significance of Mendelian ratios. Probability values
of p < 0.05 were selected to be statistically significant.
RESULTS
PECAM-1−/− mice birth rate is less than that expected by Mendelian inheritance
We generated PECAM-1−/− mice and litter-matched controls by breeding PECAM-1
heterozygotes on C57Bl6 mice background. All murine platelet experiments were performed
Dhanjal et al. Page 5
Platelets. Author manuscript; available in PMC 2007 March 19.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
with littermate-controls generated from breeding C57Bl/6J with PECAM-1−/− generating
PECAM-1+/−. Littermates were genotyped by flow cytometry of leukocytes stained with
FITC-conjugated rat anti-mouse monoclonal PECAM-1 (MEC13.3) antibody (Figure1a).
The frequency of PECAM-1−/− mice was 13 (14%) from 110 births, which was significantly
less (p<0.01) than that expected with standard Mendelian inheritance rates (Figure1b). We
are not aware of another study which has reported this observation, which may be explained
by the critical role of PECAM-1 in capacitation of human spermatozoa prior to fertilization
[37].
PECAM-1−/− platelets exhibit a small increase in aggregation to threshold concentrations
of GPVI agonists and rhodocytin
To confirm a role of PECAM-1 in platelet function, we examined platelet aggregation in
litter-matched wild-type (wt) and PECAM-1−/− platelets to the GPVI-selective agonist,
CRP, and to collagen. There was a small potentiation in the magnitude of response to
threshold and submaximal concentrations of CRP which began after a delay of 30 sec or
more (Figure2a). There was no potentiation in the magnitude or rate of response to higher
concentrations of CRP (Figure2a). Furthermore, responses to threshold and intermediate
concentrations of collagen (1-3μg/ml) were essentially unchanged for the initial 60 sec,
although these were then followed by a very minor increase in the extent of aggregation in
the absence of PECAM-1 (Figure2b). There was no different between wt and PECAM-1−/−
platelets at a higher concentration of collagen (Figure2b). Mice heterozygous for PECAM-1
expression exhibited near-normal responses to low-dose collagen and CRP (not shown)
demonstrating that 50% receptor expression is sufficient to maintain normal function.
We extended our investigation on the role of PECAM-1 in regulating platelet aggregation to
agonists which signal through other receptors. The protease thrombin stimulates activation
of mouse platelets through the PAR4 G protein-coupled receptor. Significantly, aggregation
to threshold and intermediate concentrations of thrombin was not altered in the absence of
PECAM-1 (Figure2c). The snake venom toxin rhodocytin has recently been shown to
activate platelets via the lectin receptor, CLEC-2. CLEC-2 signals via Src and Syk family
tyrosine-kinases leading to activation of PLCγ2, but in contrast to GPVI, uses a single
YXXL rather than an ITAM sequence to activate Syk [33]. Aggregation of platelets to
threshold concentrations of rhodocytin is characterised by a delay of up to several minutes
as illustrated in Figure2d. In PECAM-1−/− platelets, the time course of activation by a
threshold concentration of rhodocytin (10nM) is significantly reduced and accompanied by a
marked potentiation in magnitude of response. Similarly, the delay in activation by a ten-
fold higher concentration of rhodocytin (100nM) was also reduced, although there was no
increase in magnitude of response. The response to a higher concentration of rhodocytin
(1,000nM) was identical in control and PECAM-1−/− platelets.
The present results are in line with those of Patil et al. who reported potentiation of
aggregation in response to low concentrations of collagen and CRP but not to thrombin in
PECAM-1−/− platelets. However, we have observed a much smaller degree of potentiation,
most notably for collagen. In contrast, Jones et al. observed a delay in potentiation of
aggregation to a high concentration of collagen (30μg/ml) in the absence of PECAM-1,
which led to an increase in the overall maximal level of aggregation. In all cases,
potentiation was delayed consistent with a feedback action. The present study has also
demonstrated potentiation of aggregation to threshold and intermediate concentrations of
rhodocytin, which signals through the lectin receptor, CLEC-2. The degree of potentiation
was more marked than that observed against CRP for a threshold concentration of
rhodocytin, although this may reflect the unusually long delay in response to the snake
toxin.
Dhanjal et al. Page 6
Platelets. Author manuscript; available in PMC 2007 March 19.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Thus, the present results support a very minor role for PECAM-1 in mediating inhibition
after commencement of aggregation induced by agonists which signal through GPVI and
lectin receptors.
PECAM-1−/− platelets demonstrate enhanced spreading on CRP and fibrinogen
The major platelet integrin, αIIbβ3, also regulates PLCγ2 downstream of Src and Syk
tyrosine-kinase, albeit through a pathway that is distinct from those used by GPVI and
CLEC-2. Recently, PECAM-1 has been shown to be essential for spreading and to
contribute to clot retraction induced by outside-in signalling through αIIbβ3 [30].
Interestingly, the former result contrasts with the potentiation of spreading observed on
botracetin-VWF, which also signals through Src and Syk tyrosine-kinases, leading to
activation of PLCγ2 [10].
To investigate the role of PECAM-1 in ‘outside-in’ signalling by integrin αIIbβ3, we
investigated spreading of PECAM-1−/− platelets in real-time on fibrinogen, alongside
similar studies on CRP, and clot retraction in PRP. Mouse platelets undergo a characteristic
series of changes on an immobilised surface of CRP leading to formation of filopodia and
lamellipodia. This is exemplified in Figure3a where the majority of platelets have undergone
complete spreading by 45min. In contrast, on fibrinogen, the majority of mouse platelets
generate filopodia but fail to form distinct lamellipodia. The degree of platelet spreading is
potentiated on both surfaces in PECAM-1−/− platelets, albeit to a limited extent and after a
delay. This effect is particularly mild on fibrinogen, with a significant difference only
observed after 45min (Figure3bi-ii). Interestingly, there was no difference in spreading
between control and PECAM-1−/− platelets on fibrinogen in the presence of G protein-
coupled receptor agonist, thrombin (Figure3biii). These results therefore demonstrate that
PECAM-1 negatively regulates spreading on fibrinogen, although this effect is masked
when platelets are stimulated by a powerful G-protein receptor agonist. Further the
magnitude of potentiation is relatively minor. These results are in contrast to a recent study
which has reported that PECAM-1 is essential for platelet spreading on fibrinogen [30].
The role of PECAM-1 in clot retraction was investigated in PRP stimulated by thrombin
(10U/ml) over a course of two hours as illustrated in Figure3ci. Quantitation of the
remaining serum volume after this period 2 hours revealed no significant difference relative
to litter-matched controls (Figure3ci). In contrast, a Src family kinase inhibitor, PD0173952,
that is active in plasma, caused a small, but significant degree of inhibition at 30, 60, 90 and
120 min (Figure3cii and data not shown).
Cross-linking PECAM-1 marginally inhibits platelet aggregation
The above results provide evidence for a very minor feedback role of PECAM-1 in
regulating responses to GPVI, integrin αIIbβ3 and CLEC-2 in platelets. Physiologically,
however, the major role of PECAM-1 may not be to mediate feedback activation of
platelets, but to prevent activation at appropriate sites in the vasculature. For example,
platelet PECAM-1 could undergo a homophilic interaction with endothelial-PECAM-1,
where it is expressed at 1 million copies per endothelial cell, leading to inhibition of platelet
function [38, 39].
The effect of crosslinking of PECAM-1 on platelet activation was investigated using two
anti-PECAM-1 mAbs, PECAM-1.3 and AB468, in combination with a secondary antibody,
F(ab')2 fragment. mAb AB468 was dialysed prior to experimentation to remove azide, which
was found to inhibit platelet activation. Experiments were performed in the presence of a
F(ab')2 fragment of mAb IV.3, which blocks the low-affinity immune receptor, FcγRIIA, on
the platelet surface. Both antibodies induced a marked increase in tyrosine phosphorylation
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of PECAM-1, which was similar or slightly less than that induced by thrombin or CRP
(Figure4a). On their own, neither had an effect on platelet aggregation.
Crosslinking of PECAM-1 for varying times prior to agonist addition inhibited platelet
aggregation induced by relatively low concentrations of CRP (0.03μg/ml), thrombin (0.01U/
ml) and rhodocytin (10nM) that were just sufficient to induce near maximal platelet
aggregation. This is illustrated in Figure4bi for mAb AB468, with a similar set of data
obtained with mAb PECAM-1.3 (not shown). Cross-linking of PECAM-1 had little or no
inhibitory effect on aggregation to higher concentrations of CRP, thrombin, and rhodocytin
(Figure4bii). This is particularly striking for rhodocytin, where the concentration was only
increased by 3-fold.
The relatively weak nature of inhibition of platelet aggregation to all three agonists induced
by crosslinking of PECAM-1 prompted us to investigate the magnitude of this effect relative
to PGI2, which mediates platelet inhibition via elevation of cAMP. For these experiments,
platelets were pre-incubated with varying concentrations of PGI2 prior to stimulation with
CRP and thrombin. As illustrated in Figure5, PGI2 completely inhibited aggregation to both
agonists, with an approximately ten-fold increase in concentration being required to fully
block aggregation to the higher concentration of the two ligands. These results therefore
demonstrate that PECAM-1 mediates platelet inhibition only to very low concentrations of
CRP and thrombin, whereas PGI2 causes a more profound level of inhibition to higher
concentrations of the two stimuli. Importantly, PGI2 also markedly inhibits aggregation to
rhodocytin and spreading on fibrinogen (not shown) thereby demonstrating that it inhibits
platelet activation by the major classes of tyrosine kinase-linked receptors.
Thrombus formation is maintained in PECAM-1−/− platelets
The role of PECAM-1 in regulating platelet activation under shear conditions was
investigated using collagen-coated microcapillary tubes in a capillary-tube flow chamber at
a shear rate of 1800s−1. Blood was perfused for 3min and platelet-rich-aggregates/thrombi
imaged after perfusion by DIC microscopy before extraction for protein assay. These
conditions were chosen because they are similar to those used by Jones et al. in which a
small, potentiatory role of PECAM-1 was recorded [8]. However, in contrast, to this study,
we observed a reduction in thrombus formation in the absence of PECAM-1−/− (Figure6a),
although this did not reach statistical significance (Figure6b). Similar results were obtained
at a lower shear rate of 1000s−1 (data not shown). The lack of effect on thrombus formation,
however, is in line with a similar result for thrombus formation on VWF in the presence of
botrocetin at a similar rate of shear, 1500s−1. Furthermore, thrombus formation under shear
was reduced by approximately 90% in the presence of PGI2 (Auger & Watson unpublished
data).
DISCUSSION
The aim of the present study was to further explore the role of PECAM-1 in platelets using
both PECAM-1−/− mice and receptor crosslinking studies, and to extend this work to the
lectin-like receptor, CLEC-2, which also mediates platelet activation through PLCγ2.
Studies using PECAM-1−/− mice demonstrate that the Ig-receptor has a minor inhibitory
effect against platelet activation induced by receptors that signal through Src and Syk family
tyrosine-kinases, namely GPVI, integrin αIIbβ3 and CLEC-2, but that it has no effect on
responses to the G protein-coupled receptor agonist, thrombin. A previous study has also
shown that PECAM-1 weakly inhibits platelet activation by GPIb, which also signals
through Src and Syk family tyrosine-kinases. The inhibitory effect of PECAM-1 against all
of these receptors occurs after an initial delay consistent with a feedback mechanism. On the
other hand, crosslinking of PECAM-1 mediates inhibition to low concentrations of both
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tyrosine kinase-linked and G protein-coupled receptors, with the inhibitory effect being
overcome by higher concentrations of agonists. The relatively weak nature of these
inhibitory effects is put into perspective by studies with PGI2, which activates the G protein-
coupled IP-receptor leading to elevation of cAMP. PGI2 completely inhibited activation by
concentrations of CRP and thrombin, which were not altered in the absence of PECAM-1 or
following crosslinking of the Ig-receptor. Together, therefore, the present results emphasise
that the inhibitory role of PECAM-1 in platelets is extremely mild, thereby questioning its
likely physiological relevance. This is consistent with the observation that thrombus
formation on collagen at a high rate of shear was not altered in the absence of PECAM-1.
In qualitative terms, many of the present observations (with the exception of the critical role
of PECAM-1 in outside-in signalling by integrin αIIbβ3) are in general agreement with
previous reports, but in contrast, the overall conclusion from this study is that PECAM-1 is
unlikely to play a major role in regulating platelet activity. This conclusion is based on the
very weak nature of the potentiation that has been observed in light of the more powerful
inhibition of activation by PGI2, which elevates cAMP. Furthermore, there is also the
possibility that the weak inhibitory effect observed upon crosslinking of PECAM-1 is due to
a steric effect in view of the similar inhibition in response to thrombin and the fact that the
Ig-receptor is expressed at a very high level on the platelet surface.
To minimise differences within experimental design relative to other published studies, the
PECAM-1 knockout mice were bred on the same C57Bl/6 background as used in these
studies [8, 9]. Information on the age and sex of the mice used in other studies was not
provided [7-9]. We have performed our study using litter-matched mice of equal gender
with ages ranging from 8 to 10 weeks. Importantly, however, pilot studies demonstrated no
differences between platelet aggregation and spreading between older and younger mice.
The present study extended investigation of the role of PECAM-1 in platelet activation to
rhodocytin, which activates the lectin receptor CLEC-2. This receptor has recently been
shown to mediate platelet activation through a similar pathway to that used by GPVI,
although it requires only a single YXXL motif. Overall, the profile of inhibition of responses
to rhodocytin is similar to that of the GPVI-selective agonist, CRP, although the effect is
more dramatic, most likely because of the unusually long lag time required for platelet
activation by low concentrations of the snake venom toxin. Significantly, however, the
response to higher concentrations of rhodocytin are also not altered in the absence of
PECAM-1 or upon crosslinking of the receptor. This study has also investigated the effect of
PECAM-1 on spreading on fibrinogen and clot retraction, in view of the recent observation
that PECAM-1 is essential for filopodia formation downstream of integrin αIIbβ3 and also
plays a major role in mediating clot retraction [30]. We observed, however, weak
potentiation in the absence of PECAM-1 of spreading on fibrinogen, which was masked in
the presence of thrombin. Furthermore, we observed a slight potentiation rather than
inhibition of clot retraction in the absence of PECAM-1. The explanation for these
contrasting observations is not known, although it is noteworthy that potentiation of
spreading of PECAM-1−/− platelets was also observed in the present study against CRP and
previously against VWF-botracetin [10]. Thus, overall PECAM-1 weakly inhibits responses
to four distinct classes of receptors that signal through Src and Syk family tyrosine-kinases,
namely GPVI, GPIb, CLEC-2 and integrin αIIbβ3. The underlying basis of this inhibition,
however, is unclear in view of the recent observation that PECAM-1 does not inhibit Ca2+
elevation by the collagen receptor GPVI, thereby demonstrating that it does not interfere
with PLCγ activation [30].
In conclusion, the present study has added to the growing recognition that PECAM-1 has a
very weak feedback effect against responses to tyrosine kinase-linked receptors, but has
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brought into the question the physiological significance of this effect in view of the lack of
effect on thrombus formation, especially in light of the powerful inhibitory effect of PGI2.
The functional significance of PECAM-1 in platelets therefore remains unclear.
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Figure 1a above
Figure 1b above
Figure 1.
Genotyping of PECAM-1−/− mice.
(a) PECAM-1 expression on leukocytes stained with FITC-conjugated rat anti-mouse
monoclonal PECAM-1 antibody (MEC13.3) assessed by flow cytometry. PECAM-1+/+
(bold line), PECAM-1+/− (dashed line) and PECAM-1−/− (grey line). 10000 viable
lymphocytes were gated in each case. (b) Interbreeding heterozygote mice generated knock-
out mice with a significant reduction in the expected Mendelian frequency of PECAM-1−/−
mice (p<0.01).
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Figure 2.
PECAM-1−/− platelets show hyper-aggregation in response to stimulation with low
concentrations of CRP and rhodocytin.
Platelets from PECAM-1−/− mice and litter-matched controls were exposed to CRP,
collagen, thrombin and rhodocytin. Results are representative of 3 separate experiments.
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Figure 3cii above
Figure 3.
Spreading and clot retraction in PECAM-1−/− platelets.
(a) Spreading of PECAM-1−/− and litter-matched control platelets were analysed using DIC
microscopy after being allowed to spread on fibrinogen and CRP for 45min. (b) Time course
of spreading of PECAM-1−/− and litter-matched control platelets on (i) CRP and (ii)
fibrinogen, in the absence and presence of thrombin (iii). Increase in mean surface area (SA)
of platelets after 45min; values are shown as mean±SEM of between 115–209 platelets from
one experiment that is representative of three; * P < 0.05 relative to the corresponding
control. (c) Clot retraction in PECAM-1−/− and litter-matched control platelets: (i) time
course of contraction; and (ii) volume of extracted serum after 2 hours (n = 4).
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Figure 4b above
Figure 4.
Cross-linking of PECAM-1 inhibits platelet aggregation to low but not high concentrations
of platelet agonists.
(a) Tyrosine phosphorylation of PECAM-1 induced by CRP, thrombin and crosslinking
(XL) using two different anti-PECAM-1 antibodies, namely PECAM-1.3 or AB468.
PECAM-1 was immunoprecipitated and western-blotted for tyrosine phosphorylation as
described in the methods. (b) Crosslinking of PECAM-1 inhibits platelet aggregation
induced by low but not intermediate concentrations of CRP, thrombin and rhodocytin. Data
are representative of 3 separate experiments.
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Figure 5.
Prostacyclin (PGI2) mediates powerful inhibition of platelet aggregation.
PGI2 inhibits platelet aggregation induced by low and intermediate concentrations of CRP
and thrombin. Results are representative of three experiments.
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Figure 6a above
Figure 6b above
Figure 6.
Thrombus formation in PECAM-1−/− platelets.
PECAM-1−/− and litter-matched control platelets were flowed over collagen at a shear rate
of 1800s−1 for 3min and thrombi visualized with an inverted-stage videomicroscope. (a)
Representative images showing thrombus formation. (b) Thrombus formation was measured
using RC-DC protein assay as described in the methods. Results are shown as mean±SEM
of four experiments.
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